Catalyst Dossier · compiled by CeliA 🧫
Cara Therapeutics, Inc. (CARA)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
10
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| difelikefalin 2.0 mg | Phase 2 | Pruritus |
| CR845 0.5 mcg/kg | Phase 3 | Uremic Pruritus |
| CR845 0.25 mg Oral Tablet | Phase 2 | Chronic Kidney Diseases |
| CR845 0.25 mg | Phase 2 | Osteoarthritis |
| CR845 IV 1 mcg/kg | Phase 3 | Post Abdominal Surgery Pain |
| CR845 tablet 1 mg | Phase 2 | Osteoarthritis, Hip |
| difelikefalin 0.25 mg | Phase 2 | Pruritus |
| CR845 1 mcg/kg | Phase 3 | Uremic Pruritus |
| CR845 | Phase 3 | Postoperative Pain |
| Part A: CR845 0.5 mcg/kg | Phase 2 | Pruritus |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CARA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.